Fatal Myocarditis Following Treatment with the PD-1 Inhibitor Nivolumab

Journal of Forensic Sciences

Volumn 63, Issue 3, 2018, Pages 954-957

  Matson, Daniel R ^a   Accola, Molly A ^b   Rehrauer, William M ^a   Corliss, Robert F ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b University of Wisconsin Health   (United States)

Author keywords

autopsy; drug effects; forensic science; immunotherapy adverse effects; myocarditis immunology; myocarditis pathology; nivolumab; programmed cell death 1 receptor

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; NIVOLUMAB;

AUTOIMMUNE DISEASE; CASE REPORT; CHEMICALLY INDUCED; FATALITY; HUMAN; IMMUNOLOGY; LUNG TUMOR; MALE; MIDDLE AGED; MYOCARDITIS; NON SMALL CELL LUNG CANCER;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; AUTOIMMUNE DISEASES; CARCINOMA, NON-SMALL-CELL LUNG; FATAL OUTCOME; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MYOCARDITIS;

EID: 85046363576     PISSN: 00221198     EISSN: 15564029     Source Type: Journal    
DOI: 10.1111/1556-4029.13633     Document Type: Article

References (25)

1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12(4):252–64.
2. Brahmer JR, Hammers H, Lipson EJ. Nivolumab: Targeting PD-1 to bolster antitumor immunity. Future Oncol 2015;11(9):1307–26.
3. Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 2016;54:139–48.
4. Varricchi G, Marone G, Mercurio V, Galdiero MR, Bonaduce D, Tocchetti CG. Immune checkpoint inhibitors and cardiac toxicity: an emerging issue. Curr Med Chem 2017;24:1–13. https://doi.org/10.2174/0929867324666170407125017. Epub 2017 Apr 7.
5. Heinzerling L, Ott PA, Hodi FS, Husain AN, Tajmir-Riahi A, Tawbi H, et al. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer 2016;4:50.
6. Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 2016;375(18):1749–55.
7. Läubli H, Balmelli C, Bossard M, Pfister O, Glatz K, Zippelius A. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer 2015;3:11.
8. Schenk T, Enders M, Pollak S, Hahn R, Huzly D. High prevalence of human parvovirus B19 DNA in myocardial autopsy samples from subjects without myocarditis or dilative cardiomyopathy. J Clin Microbiol 2009;47(1):106–10.
9. Stewart GC, Lopez-Molina J, Gottumukkala RVSRK, Rosner GF, Anello MS, Hecht JL, et al. Myocardial parvovirus B19 persistence: lack of association with clinicopathologic phenotype in adults with heart failure. Circ Heart Fail 2011;4(1):71–8.
10. Wang J, Zhang W, Liu H, Wang D, Wang W, Li Y, et al. Parvovirus B19 infection associated with Hashimoto's thyroiditis in adults. J Infect 2010;60(5):360–70.
11. van Dongen JJM, Langerak AW, Brüggemann M, Evans PA, Hummel M, Lavender FL, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003;17(12):2257–317.
12. Langerak AW, Groenen PJTA, Brüggemann M, Beldjord K, Bellan C, Bonello L, et al. EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations. Leukemia 2012;26(10):2159–71.
13. Caforio ALP, Malipiero G, Marcolongo R, Iliceto S. Myocarditis: a clinical overview. Curr Cardiol Rep 2017;19(7):63.
14. Feldman AM, McNamara D. Myocarditis. N Engl J Med 2000;343(19):1388–98.
15. Kindermann I, Barth C, Mahfoud F, Ukena C, Lenski M, Yilmaz A, et al. Update on myocarditis. J Am Coll Cardiol 2012;59(9):779–92.
16. Koelzer VH, Rothschild SI, Zihler D, Wicki A, Willi B, Willi N, et al. Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors – an autopsy study. J Immunother Cancer 2016;4:13.
17. Corsello SM, Barnabei A, Marchetti P, De Vecchis L, Salvatori R, Torino F. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab 2013;98(4):1361–75.
18. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366(26):2443–54.
19. Behling J, Kaes J, Münzel T, Grabbe S, Loquai C. New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma. Melanoma Res 2017;27(2):155–8.
20. Gibson R, Delaune J, Szady A, Markham M. Suspected autoimmune myocarditis and cardiac conduction abnormalities with nivolumab therapy for non-small cell lung cancer. BMJ Case Rep 2016;2016:bcr2016216228.
21. Tadokoro T, Keshino E, Makiyama A, Sasaguri T, Ohshima K, Katano H, et al. Acute lymphocytic myocarditis with anti-PD-1 antibody nivolumab. Circ Heart Fail 2016;9(10):e003514.
22. Young NS, Brown KE. Parvovirus B19. N Engl J Med 2004;350(6):586–97.
23. Bock C-T, Klingel K, Kandolf R. Human parvovirus B19 – associated myocarditis. N Engl J Med 2010;362(13):1248–9.
24. Dettmeyer R, Kandolf R, Baasner A, Banaschak S, Eis-Hübinger AM, Madea B. Fatal parvovirus B19 myocarditis in an 8-year-old boy. J Forensic Sci 2003;48(1):183–6.
25. Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017;357(6349):409–13.